Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
Another hurdle down as EU clears AstraZeneca’s Alexion takeoverThe European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the Share XAnother hurdle down as EU clears AstraZeneca’s Alexion takeoverhttps://pharmaphorum.com/news/another-hurdle-down-as-eu-clears-astrazenecas-alexion-takeover/
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHThe mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris, Share XEHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHhttps://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/
UK competition watchdog probes AstraZeneca, Alexion mergerThe antitrust authority in the UK has launched an investigation into the proposed $39 billion takeover of US Share XUK competition watchdog probes AstraZeneca, Alexion mergerhttps://pharmaphorum.com/news/uk-competition-watchdog-probes-astrazeneca-alexion-merger/
Apellis set to take on Alexion as FDA clears PNH drug EmpaveliApellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal Share XApellis set to take on Alexion as FDA clears PNH drug Empavelihttps://pharmaphorum.com/news/apellis-set-to-take-on-alexion-as-fda-clears-pnh-drug-empaveli/
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUSNHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to Share XScotland backs NHS use of Alexion’s Ultomiris for rare disease aHUShttps://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/
AZ posts solid Q1 results as Alexion merger loomsAstraZeneca’s not-for-profit coronavirus vaccine has bit into margins in Q1, although revenues were ahead of expectations as the Share XAZ posts solid Q1 results as Alexion merger loomshttps://pharmaphorum.com/news/az-posts-solid-q1-results-as-alexion-merger-looms/
CHMP backs Roche’s Enspryng for rare nerve disease NMOSDRoche’s Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending Share XCHMP backs Roche’s Enspryng for rare nerve disease NMOSDhttps://pharmaphorum.com/news/chmp-backs-roches-enspryng-for-rare-nerve-disease-nmosd/
